Liquid Phase Peptide Synthesis (LPPS) Market Trends [2032]
Liquid Phase Peptide Synthesis (LPPS) Market Trends [2032]
Segments - Liquid Phase Peptide Synthesis (LPPS) Market by Product Type (Equipment & Services Reagents), by Application (Therapeutic Peptide Synthesis, Diagnostic Peptide Synthesis, Research and Development), by End-use Industry (Biopharmaceutical Industry, Research Laboratories, Contract Research Organizations (CROs), and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024 – 2032
Upcoming
| Report ID :HC-6680
| 4.8 Rating
| 86 Reviews
| 280 Pages
| Format :
Report Description
Market Outlook:
The global liquid phase peptide synthesis market size was USD 212.9 Million in 2023 and is likely to reach USD 413.2 Million by 2032, expanding at a CAGR of 7.8% during 2024–2032. The market growth is attributed to the increasing demand for peptide-based drugs to treat a variety of diseases creates an intense need for efficient and scalable peptide synthesis methods.
Liquid Phase Peptide Synthesis (LPPS) is a technique used to create peptides, which are chains of amino acids that play crucial roles in biological processes. Solid Phase Peptide Synthesis (SPPS), the most common method, though LPPS carries out the entire synthesis process in a liquid solution. Solution phase peptide synthesis, also known as liquid phase peptide synthesis, or LPPS, produces high-quality peptides and is cost-effective for shorter sequences of 20 amino acids or less.
The research report finds that the COVID-19 Pandemic had a significant impact on the liquid phase peptide synthesis market. The rapid spread of COVID-19 spurred a global effort to develop vaccines and treatments. Peptides emerged as promising candidates due to their potential advantages like specificity and fewer side effects compared to traditional drugs.
This surge in research and development activities for COVID-19 therapeutics significantly increased the demand for LPPS, particularly for synthesizing short peptides suitable for vaccine development and drug discovery efforts.
Macro-economic Factors
Rising R&D Activities
Research & development (R&D) plays a significant role in determining the growth and future advancements of a country or region. R&D activities are an approach to scientific innovation that ultimately makes a meaningful difference in the lives of people. A majority of the key players in the market invest some part of their total sales in R&D activities aiming to discover and innovate new product portfolios. R&D investments, in terms of new products & services, improved processes, and new ways to interact with customers resulting in high profits and low costs. R&D plays an enormous role from drug discovery to final approval and marketing, where regulatory bodies act as checkpoints. R&D has a major impact on the overall market.
Global Liquid Phase Peptide Synthesis Market Dynamics
Major Drivers: Growing Demand for Peptide-based Therapeutics
Demand for peptide-based therapeutics is increasing due to a variety of factors, including the rising prevalence of chronic diseases such as cancer, diabetes, and obesity. There is an increasing need for new, more effective treatments for these diseases. Advances in peptide synthesis technology. Increased government and industry funding for peptide therapeutics research.
Major Drivers: Emerging Applications & Focus on Personalized Medicine
LPPS is finding new applications outside of therapeutics, such as the development of peptide-based biomaterials and research tools, which is expanding the market. LPPS provides greater flexibility for synthesizing customized peptides for personalized medicine approaches.
Existing Restraints: Scalability Limitations and High Initial Investment
The cost of LPPS equipment, particularly automated synthesizers, can be a major barrier to entry, especially for smaller research labs or startups. The elaborate purification procedures in LPPS result in higher labor and solvent usage, which raises overall production costs. Scaling up these processes exacerbates the costs. Furthermore, LPPS has potential for specific applications, but its scalability constraints require cautious consideration for large-scale peptide production. This reduces the potential user base and impedes overall market growth.
Emerging Opportunities: Technological Advancements and Automation
Continuous advancements in SPPS technology are leading to increased automation, improved resins and reagents, and focus on continuous flow synthesis. The development of novel purification methods such as Soluble Tag Technology and Group-Assisted Purification (GAP) Peptide Synthesis (GAPPS) simplifies isolation and lowers costs, making LPPS more appealing for large-scale production. The integration of automation and robotics into LPPS workflows streamlines the process, increasing efficiency and consistency, particularly for repetitive tasks.
Scope of the Global Liquid Phase Peptide Synthesis Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Liquid Phase Peptide Synthesis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017–2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
Product Type, Application, and End-use Industry |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
AmbioPharm Inc.; Aragen Life Sciences Ltd.; Bachem; Biotage; Enable Injections; GenScript; Nissan Chemical Corporation; ProteoGenix; Spectrum Chemical; and others. |
Market Segment Insights
Product Type Analysis
Based on Product Type, the global Liquid Phase Peptide Synthesis market is segmented into equipment & services and reagents. In 2023, reagents accounted for the highest proportion of the liquid Phase Peptide Synthesis market. This segment holds the largest market share due to biopharmaceutical companies and research labs need to constantly replenish reagents and consumables used in peptide synthesis, leading to higher overall sales. A wide range of specialized amino acids, catalysts, solvents, and other consumables are required for LPPS, contributing to the segment size.
Application Analysis
On the basis of Application, the global liquid phase peptide synthesis market is divided into therapeutic peptide synthesis, diagnostic peptide synthesis, and research and development. The therapeutics segment is widely used in liquid phase peptide therapeutics for a variety of diseases.
The pharmaceutical industry continual efforts to harness peptides for targeted therapies and the development of biologics further bolster this segment’s dominance in the market. According to the study, the percentage of cancer patients in the US who qualify for and benefit from genome-targeted therapy has grown over time, rising from a projected 2.7 in 2006 to 7% in 2020.
End-use Industry Channel Analysis
Based on End-use Industry, the global Liquid Phase Peptide Synthesis market is bifurcated into Biopharmaceutical Industry, Research Laboratories, Contract Research Organizations (CROs), and Others.
Biopharmaceutical Industry segment is anticipated to holds 44.3%share of the market in the year 2023. This is owing to the extensive use of peptides in drug development and manufacturing. For instance, since 2000, 33 non-insulin peptide medications have received approvals across the globe. Furthermore, these peptide medications are no longer just natural amino acid compositions or hormone mimics.
Additionally, LPSS is useful for the rapid prototyping and development of new peptide drugs. In contrast to SPPS, which is batch-based, LPPS can be adapted to continuous flow processes, making it ideal for large-scale production. This is relevant if a biopharmaceutical company needs to produce large amounts of a specific peptide therapeutic.
Regional Outlook
In terms of region, the global Liquid Phase Peptide Synthesis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2023, followed by Europe and Asia Pacific.
The North American liquid phase peptide synthesis market is primarily driven by strong research and development activities, as the region observes widespread use of peptides in drug discovery and manufacturing by pharmaceutical and biotechnology companies. By 2032 North America liquid-phase peptide synthesis market is estimated to account for 39% of the revenue share. The research and development expenditure in the US pharmaceutical industry will be around 110 billion by the year 2022.
Segments
The global Liquid Phase Peptide Synthesis market has been segmented on the basis ofProduct Type
- Equipment & Services
- Reagents
Application
- Therapeutic Peptide Synthesis
- Diagnostic Peptide Synthesis
- Research and Development
End-use Industry
- Biopharmaceutical Industry
- Manufacturing Existing Peptide Drug
- Developing New Peptide Drug
- Fragment-Based Drug Discovery
- Others
- Research Laboratories
- Contract Research Organizations (CROs)
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- AmbioPharm Inc.
- Aragen Life Sciences Ltd.
- Bachem
- Biotage
- Enable Injections
- GenScript
- Nissan Chemical Corporation
- ProteoGenix
- Spectrum Chemical
- Others
Competitive Landscape
Key players competing in the global Liquid Phase Peptide Synthesis market are AmbioPharm Inc.; Aragen Life Sciences Ltd.; Bachem; Biotage; Enable Injections; GenScript; Nissan Chemical Corporation; ProteoGenix; Spectrum Chemical; and others.
These companies adopted development strategies including mergers, partnerships, acquisitions, Product Type launches, Production expansion, and collaboration to expand their consumer base across the globe.
Frequently Asked Questions
The base year considered for the global Liquid Phase Peptide Synthesis market report is 2023. The complete analysis period is 2017 to 2032, wherein, 2017 and 2022 are the historic years, and the forecast is provided from 2024 to 2032.
In addition to market size (in US$ Million), company market share (in % for the base year 2023) is available in the report. Moreover, additional data analysis can be provided on request.
The COVID-19 pandemic had a significant impact on the Liquid Phase Peptide Synthesis market. Global lockdowns and travel restrictions disrupted the supply chain of peptide synthesis. Lockdowns and restrictions on movement caused temporary closures of research laboratories and pharmaceuticals companies. However, The COVID-19 pandemic has prompted key pharmaceutical and biotechnology companies, as well as players in the peptide synthesis market, to invest in therapeutic and peptide-based vaccine research and development.
AmbioPharm Inc.; Aragen Life Sciences Ltd.; Bachem; Biotage; Enable Injections; GenScript; Nissan Chemical Corporation; ProteoGenix; Spectrum Chemical; and others.
Rising R&D Activities is expected to act as macroeconomic factors for the market.
According to this Growth Market Reports report, the Liquid Phase Peptide Synthesis market is likely to register a CAGR of 7.8% during the forecast period 2023-2032, with an anticipated valuation of USD 413.2 Million by the end of 2032.
Growing demand for peptide-based therapeutics and emerging applications & focus on personalized medicine are the factors driving the market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liquid Phase Peptide Synthesis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liquid Phase Peptide Synthesis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liquid Phase Peptide Synthesis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liquid Phase Peptide Synthesis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liquid Phase Peptide Synthesis Market Size & Forecast, 2017-2032
4.5.1 Liquid Phase Peptide Synthesis Market Size and Y-o-Y Growth
4.5.2 Liquid Phase Peptide Synthesis Market Absolute $ Opportunity
4.6 Global Liquid Phase Peptide Synthesis Market: Impact Of Key Regulations
Chapter 5 Global Liquid Phase Peptide Synthesis Market Analysis and Forecast By Product Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Product Type
5.1.2 Basis Point Share (BPS) Analysis By Product Type
5.1.3 Absolute $ Opportunity Assessment By Product Type
5.2 Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
5.2.1 Equipment & Services
5.2.2 Reagents
5.3 Market Attractiveness Analysis By Product Type
Chapter 6 Global Liquid Phase Peptide Synthesis Market Analysis and Forecast By Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Application
6.1.2 Basis Point Share (BPS) Analysis By Application
6.1.3 Absolute $ Opportunity Assessment By Application
6.2 Liquid Phase Peptide Synthesis Market Size Forecast By Application
6.2.1 Therapeutic Peptide Synthesis
6.2.2 Diagnostic Peptide Synthesis
6.2.3 Research and Development
6.3 Market Attractiveness Analysis By Application
Chapter 7 Global Liquid Phase Peptide Synthesis Market Analysis and Forecast By End-use Industry
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End-use Industry
7.1.2 Basis Point Share (BPS) Analysis By End-use Industry
7.1.3 Absolute $ Opportunity Assessment By End-use Industry
7.2 Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
7.2.1 Biopharmaceutical Industry
7.2.1.1 Manufacturing Existing Peptide Drug
7.2.1.2 Developing New Peptide Drug
7.2.1.3 Fragment-Based Drug Discovery
7.2.1.4 Others
7.2.2 Research Laboratories
7.2.3 Contract Research Organizations (CROs)
7.2.4 Others
7.3 Market Attractiveness Analysis By End-use Industry
Chapter 8 Global Liquid Phase Peptide Synthesis Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Liquid Phase Peptide Synthesis Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Liquid Phase Peptide Synthesis Analysis and Forecast
10.1 Introduction
10.2 North America Liquid Phase Peptide Synthesis Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
10.6.1 Equipment & Services
10.6.2 Reagents
10.7 Basis Point Share (BPS) Analysis By Product Type
10.8 Absolute $ Opportunity Assessment By Product Type
10.9 Market Attractiveness Analysis By Product Type
10.10 North America Liquid Phase Peptide Synthesis Market Size Forecast By Application
10.10.1 Therapeutic Peptide Synthesis
10.10.2 Diagnostic Peptide Synthesis
10.10.3 Research and Development
10.11 Basis Point Share (BPS) Analysis By Application
10.12 Absolute $ Opportunity Assessment By Application
10.13 Market Attractiveness Analysis By Application
10.14 North America Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
10.14.1 Biopharmaceutical Industry
10.14.1.1 Manufacturing Existing Peptide Drug
10.14.1.2 Developing New Peptide Drug
10.14.1.3 Fragment-Based Drug Discovery
10.14.1.4 Others
10.14.2 Research Laboratories
10.14.3 Contract Research Organizations (CROs)
10.14.4 Others
10.15 Basis Point Share (BPS) Analysis By End-use Industry
10.16 Absolute $ Opportunity Assessment By End-use Industry
10.17 Market Attractiveness Analysis By End-use Industry
Chapter 11 Europe Liquid Phase Peptide Synthesis Analysis and Forecast
11.1 Introduction
11.2 Europe Liquid Phase Peptide Synthesis Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
11.6.1 Equipment & Services
11.6.2 Reagents
11.7 Basis Point Share (BPS) Analysis By Product Type
11.8 Absolute $ Opportunity Assessment By Product Type
11.9 Market Attractiveness Analysis By Product Type
11.10 Europe Liquid Phase Peptide Synthesis Market Size Forecast By Application
11.10.1 Therapeutic Peptide Synthesis
11.10.2 Diagnostic Peptide Synthesis
11.10.3 Research and Development
11.11 Basis Point Share (BPS) Analysis By Application
11.12 Absolute $ Opportunity Assessment By Application
11.13 Market Attractiveness Analysis By Application
11.14 Europe Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
11.14.1 Biopharmaceutical Industry
11.14.1.1 Manufacturing Existing Peptide Drug
11.14.1.2 Developing New Peptide Drug
11.14.1.3 Fragment-Based Drug Discovery
11.14.1.4 Others
11.14.2 Research Laboratories
11.14.3 Contract Research Organizations (CROs)
11.14.4 Others
11.15 Basis Point Share (BPS) Analysis By End-use Industry
11.16 Absolute $ Opportunity Assessment By End-use Industry
11.17 Market Attractiveness Analysis By End-use Industry
Chapter 12 Asia Pacific Liquid Phase Peptide Synthesis Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Liquid Phase Peptide Synthesis Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
12.6.1 Equipment & Services
12.6.2 Reagents
12.7 Basis Point Share (BPS) Analysis By Product Type
12.8 Absolute $ Opportunity Assessment By Product Type
12.9 Market Attractiveness Analysis By Product Type
12.10 Asia Pacific Liquid Phase Peptide Synthesis Market Size Forecast By Application
12.10.1 Therapeutic Peptide Synthesis
12.10.2 Diagnostic Peptide Synthesis
12.10.3 Research and Development
12.11 Basis Point Share (BPS) Analysis By Application
12.12 Absolute $ Opportunity Assessment By Application
12.13 Market Attractiveness Analysis By Application
12.14 Asia Pacific Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
12.14.1 Biopharmaceutical Industry
12.14.1.1 Manufacturing Existing Peptide Drug
12.14.1.2 Developing New Peptide Drug
12.14.1.3 Fragment-Based Drug Discovery
12.14.1.4 Others
12.14.2 Research Laboratories
12.14.3 Contract Research Organizations (CROs)
12.14.4 Others
12.15 Basis Point Share (BPS) Analysis By End-use Industry
12.16 Absolute $ Opportunity Assessment By End-use Industry
12.17 Market Attractiveness Analysis By End-use Industry
Chapter 13 Latin America Liquid Phase Peptide Synthesis Analysis and Forecast
13.1 Introduction
13.2 Latin America Liquid Phase Peptide Synthesis Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
13.6.1 Equipment & Services
13.6.2 Reagents
13.7 Basis Point Share (BPS) Analysis By Product Type
13.8 Absolute $ Opportunity Assessment By Product Type
13.9 Market Attractiveness Analysis By Product Type
13.10 Latin America Liquid Phase Peptide Synthesis Market Size Forecast By Application
13.10.1 Therapeutic Peptide Synthesis
13.10.2 Diagnostic Peptide Synthesis
13.10.3 Research and Development
13.11 Basis Point Share (BPS) Analysis By Application
13.12 Absolute $ Opportunity Assessment By Application
13.13 Market Attractiveness Analysis By Application
13.14 Latin America Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
13.14.1 Biopharmaceutical Industry
13.14.1.1 Manufacturing Existing Peptide Drug
13.14.1.2 Developing New Peptide Drug
13.14.1.3 Fragment-Based Drug Discovery
13.14.1.4 Others
13.14.2 Research Laboratories
13.14.3 Contract Research Organizations (CROs)
13.14.4 Others
13.15 Basis Point Share (BPS) Analysis By End-use Industry
13.16 Absolute $ Opportunity Assessment By End-use Industry
13.17 Market Attractiveness Analysis By End-use Industry
Chapter 14 Middle East & Africa (MEA) Liquid Phase Peptide Synthesis Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Liquid Phase Peptide Synthesis Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Liquid Phase Peptide Synthesis Market Size Forecast By Product Type
14.6.1 Equipment & Services
14.6.2 Reagents
14.7 Basis Point Share (BPS) Analysis By Product Type
14.8 Absolute $ Opportunity Assessment By Product Type
14.9 Market Attractiveness Analysis By Product Type
14.10 Middle East & Africa (MEA) Liquid Phase Peptide Synthesis Market Size Forecast By Application
14.10.1 Therapeutic Peptide Synthesis
14.10.2 Diagnostic Peptide Synthesis
14.10.3 Research and Development
14.11 Basis Point Share (BPS) Analysis By Application
14.12 Absolute $ Opportunity Assessment By Application
14.13 Market Attractiveness Analysis By Application
14.14 Middle East & Africa (MEA) Liquid Phase Peptide Synthesis Market Size Forecast By End-use Industry
14.14.1 Biopharmaceutical Industry
14.14.1.1 Manufacturing Existing Peptide Drug
14.14.1.2 Developing New Peptide Drug
14.14.1.3 Fragment-Based Drug Discovery
14.14.1.4 Others
14.14.2 Research Laboratories
14.14.3 Contract Research Organizations (CROs)
14.14.4 Others
14.15 Basis Point Share (BPS) Analysis By End-use Industry
14.16 Absolute $ Opportunity Assessment By End-use Industry
14.17 Market Attractiveness Analysis By End-use Industry
Chapter 15 Competition Landscape
15.1 Liquid Phase Peptide Synthesis Market: Competitive Dashboard
15.2 Global Liquid Phase Peptide Synthesis Market: Market Share Analysis, 2023
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 AmbioPharm Inc.
15.3.2 Aragen Life Sciences Ltd.
15.3.3 Bachem
15.3.4 Biotage
15.3.5 Enable Injections
15.3.6 GenScript
15.3.7 Nissan Chemical Corporation
15.3.8 ProteoGenix
15.3.9 Spectrum Chemical
15.3.10 Others
Methodology
Related Reports
Some other reports from this category!
Our Clients
